$20.970
+0.010 (+0.05%)Zum Schluss
INVA-News
INVA-Events
Innoviva Reports Q2 Revenue of $119.6M, Beating Expectations
Reports Q2 revenue $119.6M, consensus $110.98M. "Innoviva delivered another strong quarter, supported by durable cash generation from our royalty portfolio and continued excellent commercial momentum at IST, which achieved 46% year-over-year net product sales growth, including 26% growth in U.S. sales. We remain on track to achieve at least $150 million in IST U.S. net product sales in 2026, reflecting the differentiation of our marketed critical care and infectious disease portfolio and robust execution," said Pavel Raifeld, Chief Executive Officer of Innoviva.
Nortiva Bio Launches Long-Acting Oral Drug Development Platform
Nortiva Bio "announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX(TM) drug delivery platform. Nortiva's LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. This advancement can optimize efficacy and safety, improve medication adherence, and positively impact patients' quality of life. Nortiva is a wholly owned subsidiary of Innoviva, which acquired the LYNX platform from Lyndra Therapeutics, Inc. in 2025."
Innoviva Signs Exclusive Distribution Agreement with Dr. Reddy's for XACDURO
Innoviva Specialty Therapeutics, a subsidiary of Innoviva (INVA), announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories (RDY) for the development and commercialization of XACDURO, co-packaged for intravenous use, in South and Central America, the Caribbean, Russia and Commonwealth of Independent States countries. Under the terms of the agreement, Dr. Reddy's will be responsible for development, regulatory and commercialization activities in the licensed territory. Innoviva Specialty Therapeutics will retain rights to XACDURO in all unlicensed territories and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales in the licensed territory.
Innoviva Reports Q1 Revenue of $98M
Reports Q1 revenue $98M, consensus $101.56M. "We delivered a strong start to 2026, driven by the resilience of our royalty portfolio, continued excellent commercial progress at IST, and meaningful value creation across our strategic healthcare assets," said Pavel Raifeld, Chief Executive Officer of Innoviva. "IST achieved 37% year-over-year net product sales growth in the first quarter of 2026, including 29% growth in U.S. sales."
Innoviva Q4 Revenue $114.6M Exceeds Expectations
Reports Q4 revenue $114.6M, consensus $102.6M. The company said, "2025 marked an excellent year for Innoviva, demonstrating strength across all areas of our business, with 15% revenue growth to over $400 million and net income exceeding $270 million. Our royalty business continued to provide stable and resilient cash flow, while IST generated 47% year-over-year U.S. sales growth to $119 million. We expanded our commercial portfolio with the successful mid-2025 launch of ZEVTERA in the U.S., received nominations for two of our products for the prestigious 2025 Prix Galien USA Award, and ended the year on an exciting note with the FDA approval of our fifth product, NUZOLVENCE, a single-dose oral treatment for uncomplicated urogenital gonorrhea that addresses a critical public health challenge in light of the global rise of gonococcal drug resistance. We are excited about our growth prospects and anticipate $150 million or more in IST U.S. net product sales in 2026. Our portfolio of strategic assets remains a key platform for long-term growth and differentiation, demonstrated by significant advances and value creation at Armata Pharmaceuticals. Overall, we remain a well-capitalized company with multiple value-accretive capital deployment opportunities in our current business, novel assets, and capital strategies, including a recently announced $125 million share repurchase program. We look forward to multiple inflection points across Innoviva's portfolio in the year ahead."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.